170 related articles for article (PubMed ID: 17620721)
1. Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent.
Li P; Rogers T; Smiley D; DiMarchi RD; Zhang F
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Jul; 63(Pt 7):599-601. PubMed ID: 17620721
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the native glucagon sequence for medicinal purposes.
Chabenne JR; DiMarchi MA; Gelfanov VM; DiMarchi RD
J Diabetes Sci Technol; 2010 Nov; 4(6):1322-31. PubMed ID: 21129326
[TBL] [Abstract][Full Text] [Related]
3. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Holz GG; Chepurny OG
Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
[TBL] [Abstract][Full Text] [Related]
5. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
6. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Sinclair EM; Drucker DJ
Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
[TBL] [Abstract][Full Text] [Related]
7. NN-2211 Novo Nordisk.
Mark M
IDrugs; 2003 Mar; 6(3):251-8. PubMed ID: 12789615
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
Meier JJ; Gallwitz B; Nauck MA
BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
[TBL] [Abstract][Full Text] [Related]
9. Crystallization and preliminary diffraction studies of malate dehydrogenase from Streptomyces aureofaciens.
Mikulásová D; Tomásková N; Maderová J; Kollárová M
Protein Pept Lett; 2006; 13(2):207-10. PubMed ID: 16472087
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
12. The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ; Nauck MA
Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
Nauck MA
Acta Diabetol; 1998 Oct; 35(3):117-29. PubMed ID: 9840447
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Baggio LL; Drucker DJ
Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
[TBL] [Abstract][Full Text] [Related]
16. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ
Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic.
Freyse EJ; Knospe S; Becher T; El Hag O; Göke B; Fischer U
Metabolism; 1999 Jan; 48(1):134-7. PubMed ID: 9920158
[TBL] [Abstract][Full Text] [Related]
18. Crystallization and preliminary X-ray analysis of Streptococcus pneumoniae hyaluronate lyase.
Jedrzejas MJ; Chantalat L; Mewbourne RB
J Struct Biol; 1998 Jan; 121(1):73-5. PubMed ID: 9573623
[TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
20. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].
Ahrén B
Lakartidningen; 2005 Feb 21-27; 102(8):545-9. PubMed ID: 15786905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
